Oncolytics Biotech Inc. ONC.TO

ONC.TO Company Overview

Oncolytics Biotech Inc. is a Canadian biotechnology company focused on the development of immuno-oncology therapies for the treatment of cancer. The company’s core asset is pelareorep, a systemically delivered oncolytic immunotherapy derived from reovirus technology that is designed to selectively replicate in and destroy cancer cells while stimulating anti-tumor immune responses. Oncolytics operates within the biotechnology, oncology therapeutics, and cancer immunotherapy industries, with research emphasis on combination therapies involving checkpoint inhibitors, chemotherapy, and targeted agents.

The company primarily generates value through clinical-stage drug development, strategic research collaborations, licensing arrangements, and capital market financing rather than commercial product sales. Its principal customer and partner ecosystem includes pharmaceutical companies, cancer research institutions, oncology clinicians, and investors in life sciences markets. Founded in 1998 and headquartered in Calgary, Alberta, Oncolytics evolved from early-stage viral oncology research into a clinical-stage immunotherapy developer with multiple international clinical studies evaluating pelareorep in breast cancer, pancreatic cancer, gastrointestinal cancers, and other solid tumors. The company’s positioning is tied to its focus on intravenously deliverable oncolytic virus therapies and its strategy of integrating immune activation with existing oncology treatment standards.